• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 1 - Diagnosis and Prognosis of Multiple Myeloma

Article

Moderator Michael Chernew, PhD, co-editor-in-chief, The American Journal of Managed Care, and professor, Leonard D. Schaeffer School of Healthcare Policy, Harvard, leads a panel discussion on multiple myeloma.

Moderator Michael Chernew, PhD, co-editor-in-chief, The American Journal of Managed Care, and professor, Leonard D. Schaeffer School of Healthcare Policy, Harvard, leads a panel discussion on multiple myeloma. He is joined by panel experts Jack Goldberg, MD, clinical professor of medicine and chief, Division of Hematology and Medical Oncology, Penn Presbyterian Medical Center; Shaji K. Kumar, MD, professor of medicine and consultant, Division of Hematology and Blood and Marrow Transplantation, Mayo Clinic; Gene Reeder, Rph, PhD, director, Managed Care Networks, Xcenda; and Anne Quinn Young, MPH, vice president of development and strategic partnerships, Multiple Myeloma Research Foundation (MMRF).

The panelists begin with a general discussion that focuses on the diagnosis and prognosis of multiple myeloma, including if early diagnosis is possible. Dr Kumar begins by analyzing whether there is evidence for familial myeloma.

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Jonathan E. Levitt, Esq, Frier Levitt, LLC
Judy Alberto, MHA, RPh, BCOP, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Emily Touloukian, DO, Coastal Cancer Center
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.